185 related articles for article (PubMed ID: 36596264)
1. Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
Albert SG; Wood EM; Ahir V
Diabetes Metab Syndr; 2023 Jan; 17(1):102696. PubMed ID: 36596264
[TBL] [Abstract][Full Text] [Related]
2. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.
Yoshida Y; Joshi P; Barri S; Wang J; Corder AL; O'Connell SS; Fonseca VA
J Diabetes Complications; 2022 Aug; 36(8):108255. PubMed ID: 35817678
[TBL] [Abstract][Full Text] [Related]
3. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM.
McKee A; Al-Khazaali A; Albert SG
J Endocr Soc; 2020 May; 4(5):bvaa037. PubMed ID: 32342023
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
6. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
Seijas-Amigo J; Salgado-Barreira Á; Castelo-Dominguez R; Pérez-Álvarez MT; Ponce-Piñón B; Fernández-Silva M; Rodríguez-Barreiro M; Pereira-Pía M; Iglesias-Moreno JM; Gago-García M; Montáns-García R; Fernandez-Perez A; FragaGayoso D; Fernandez-Montenegro M; Riveiro-Barciela B; Rilla-Villar N; Cordero A; RodríguezMañero M; González-Juanatey JR
Prim Care Diabetes; 2023 Aug; 17(4):366-372. PubMed ID: 37230813
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
8. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus.
Grewal S; Zaman N; Borgatta L; Nudy M; Foy AJ; Peterson B
Am J Cardiol; 2021 Sep; 154():48-53. PubMed ID: 34266665
[TBL] [Abstract][Full Text] [Related]
10. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Sesti G; Mannucci E; Monami M
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1106-1114. PubMed ID: 32448716
[TBL] [Abstract][Full Text] [Related]
11. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
[TBL] [Abstract][Full Text] [Related]
12. Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
Wang F; Mao Y; Wang H; Liu Y; Huang P
Clin Drug Investig; 2022 Jan; 42(1):17-28. PubMed ID: 34894326
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
[TBL] [Abstract][Full Text] [Related]
14. Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
Updike WH; Pane O; Franks R; Saber F; Abdeen F; Balazy DD; Carris NW
Drugs; 2021 Jun; 81(8):881-893. PubMed ID: 33929717
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
Duan XY; Liu SY; Yin DG
Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.
Di Dalmazi G; Coluzzi S; Baldassarre MPA; Ghit A; Graziano G; Rossi MC; Ciappini B; Milo M; Carrieri F; Nicolucci A; Consoli A; Formoso G
Front Endocrinol (Lausanne); 2022; 13():892702. PubMed ID: 35909534
[TBL] [Abstract][Full Text] [Related]
17. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
20. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
